scholarly journals Hypermethylation of brain natriuretic peptide gene is associated with the risk of rheumatic heart disease

2017 ◽  
Vol 37 (1) ◽  
Author(s):  
Ni Li ◽  
Dawei Zheng ◽  
Lebo Sun ◽  
Huoshun Shi ◽  
Xiuying Zhu ◽  
...  
Keyword(s):  
Heart Disease ◽  
Brain Natriuretic Peptide ◽  
Rheumatic Heart Disease ◽  
Natriuretic Peptide ◽  
Anticoagulant Therapy ◽  
Significant Difference ◽  
Term Administration ◽  
Promoter Dna ◽  
Peptide Gene ◽  
Rheumatic Heart

To investigate the contribution of brain natriuretic peptide (BNP) promoter DNA methylation to the risk of rheumatic heart disease (RHD) and the influence of warfarin anticoagulant therapy on BNP methylation levels for RHD patients after surgery. BNP methylation levels were determined by bisulfite pyrosequencing from plasma samples of RHD patients compared with healthy controls. Several factors influencing the RHD patients were included like age, smoking and cholesterol levels. A fragment of five CG sites (CpG1–5) in the promoter region of BNP gene was measured. BNP gene hypermethylation was found in CpG4 and CpG5 in RHD patients compared with non-RHD controls. A significant difference was also observed between RHD patients with long-term administration of warfarin and RHD patients who had recently undergone an operation. Moreover, single CpG4 and CpG5 analysis revealed a significant increase in methylation levels in men. BNP gene body hypermethylation is associated with the risk of RHD, and also influenced by the warfarin anticoagulant therapy of RHD patients after surgery, which could represent novel and promising targets for therapeutic development.

Plasma brain natriuretic peptide levels in patients with rheumatic heart disease

2004 ◽  
Vol 6 (6) ◽  
pp. 757-760 ◽  
Author(s):  
Zehra Gölbaþý ◽  
Özgül Uçar ◽  
Ayşe Geçer Yüksel ◽  
Okan Gülel ◽  
Sinan Aydoğdu ◽  
...  
Keyword(s):  
Heart Disease ◽  
Brain Natriuretic Peptide ◽  
Rheumatic Heart Disease ◽  
Natriuretic Peptide ◽  
Plasma Brain Natriuretic Peptide ◽  
Rheumatic Heart

PS287 Aminoterminal Pro-Brain Natriuretic Peptide in Children with Latent Rheumatic Heart Disease

Global Heart ◽  
2016 ◽  
Vol 11 (2) ◽  
pp. e63
Author(s):  
J. Zachariah ◽  
T. Aliku ◽  
A. Scheel ◽  
B.S. Hasan ◽  
P. Lwabi ◽  
...  
Keyword(s):  
Heart Disease ◽  
Brain Natriuretic Peptide ◽  
Rheumatic Heart Disease ◽  
Natriuretic Peptide ◽  
Rheumatic Heart

scholarly journals Amino-terminal pro-brain natriuretic peptide in children with latent rheumatic heart disease

2016 ◽  
Vol 9 (2) ◽  
pp. 120 ◽  
Author(s):  
JustinP Zachariah ◽  
Twalib Aliku ◽  
Amy Scheel ◽  
BabarS Hasan ◽  
Peter Lwabi ◽  
...  
Keyword(s):  
Heart Disease ◽  
Brain Natriuretic Peptide ◽  
Rheumatic Heart Disease ◽  
Natriuretic Peptide ◽  
Amino Terminal ◽  
Rheumatic Heart

scholarly journals Mean Levels of B-type Natriuretic Peptide (BNP) in Patients with Mitral Stenosis Caused by Rheumatic Heart Disease

2021 ◽  
pp. 96-102
Author(s):  
Altaf Hussain ◽  
Faraz Farooq Memon ◽  
Iftikhar Ahmed ◽  
Syed Ahsan Raza ◽  
Lajpat Rai ◽  
...  
Keyword(s):  
Heart Disease ◽  
Rheumatic Heart Disease ◽  
Natriuretic Peptide ◽  
Mitral Stenosis ◽  
Final Analysis ◽  
Severe Intensity ◽  
The Mean ◽  
Valvular Lesion ◽  
Rheumatic Heart ◽  
Valve Area

Objective: Mitral stenosis caused by rheumatic heart disease (RHD) is the most common cause of valvular lesion in adults and prevalent in developing countries like Pakistan. Higher natriuretic peptide (BNP) levels can be observed in patients with moderate to severe untreated mitral stenosis and are associated with higher rates of morbidity and mortality. That is why this study aims to determine the association between levels of pro-BNP with severity (mild. Moderate, and severe) of mitral stenosis. Patients and Methods: This was a clinical prospective study carried out in the department of adult cardiology, national institute of cardiovascular diseases, Karachi from 8th august 2019 to 7th February 2020. Total 68 patients of either gender with age between 25-70 years had mitral stenosis of moderate to severe intensity (mitral valve area ≤1.5 cm2), diagnosed on echocardiography were included for final analysis. A simple blood sample was taken for the assessment of pro-BNP levels. Questionnaire was used for demographic & clinical data collection and analysed using SPSS version 22.0. Results: The overall mean age of study subjects was 42.21±11.50 years, ranging from 25 – 70 years. Among them, females were prevalent (n = 43, 63.2%). The overall mean serum BNP level was 1071.12±807.26 pg/ml and the mean difference of serum BNP level was not significant among groups of gender, age, and diabetes mellitus with p>0.05. Significantly raised levels of BNP were observed in patients with severe mitral stenosis as compared to moderate mitral stenosis, p<0.05 Conclusion: In conclusion, the mean BNP levels were higher in patients with severe Mitral Stenosis. Therefore, BNP may be used to complement the clinical and echocardiographic assessments in patients with Mitral Stenosis.

scholarly journals Brain natriuretic peptide in pregnant women with heart disease

2019 ◽  
Vol 13 (1) ◽  
pp. 25-29
Author(s):  
Karanvir Singh ◽  
Pooja Sikka ◽  
Vanita Suri ◽  
Rishikesh Prasad ◽  
Madhu Khullar ◽  
...  
Keyword(s):  
Heart Failure ◽  
Adverse Event ◽  
Heart Disease ◽  
Adverse Events ◽  
Brain Natriuretic Peptide ◽  
Pregnant Women ◽  
Natriuretic Peptide ◽  
Cardiac Events ◽  
Plasma Brain Natriuretic Peptide ◽  
Rheumatic Heart

Background Plasma brain natriuretic peptide levels were prospectively studied in pregnant women with heart disease. Methods Fifty pregnant women with heart disease and 25 controls were evaluated at 24 weeks or under, 30–32 weeks, 34 weeks or more of gestation, and 6 weeks postpartum. Adverse maternal cardiac events were hospitalization for worsening heart failure, stroke, and death. Results Thirty-eight (76%) women had rheumatic heart disease. Plasma brain natriuretic peptide levels were (in cases and controls) 118.3 ± 46.5 pg/ml and 66.3 ± 15.9 pg/ml (at 24 weeks or under), 124.8 ± 30.4 pg/ml and 68.4 ± 16.5 pg/ml (30–32 weeks), 135.8 ± 34.9 pg/ml and 68.6 ± 15.6 pg/ml (34 weeks or more), and 110.1 ± 21.9 pg/ml and 65.0 ± 16.1 pg/ml (6 weeks postpartum) (p = .0001). Eighteen women had adverse events. Of these, only 1 had a level less than 100 pg/ml, 12 were between 100 and 200 pg/ml, and 5 more than 200 pg/ml. Conclusions Plasma brain natriuretic peptide levels were higher in women with heart disease at all periods of gestation as well as six weeks postpartum. No woman with a plasma brain natriuretic peptide levels of 98 pg/ml or less had an adverse event.

scholarly journals Effect of cardiac rhythm on serum levels of the inflammatory mediators; Interleukin-6 and C-Reactive Protein in patients with chronic rheumatic heart disease

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
A M Y Mohammad ◽  
O A Rifaie ◽  
M A Hamza ◽  
S A Amin
Keyword(s):  
Heart Disease ◽  
Rheumatic Heart Disease ◽  
Inflammatory Mediators ◽  
Cardiac Rhythm ◽  
Serum Levels ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Significant Difference ◽  
Long Acting ◽  
Rheumatic Heart

Abstract Background Rheumatic fever has a marked tendency to recur leading to high risk of chronic heart lesions or worsening lesions in patients with previous rheumatic heart disease. For secondary prevention of RF, long acting penicillin can be used. Some rheumatic heart disease patients suffer from atrial fibrillation. Cardiac rhythm may affect the response of the body to the long acting penicillin, so it would be helpful to study the effect of cardiac rhythm on serum levels of inflammatory mediators in patients with chronic rheumatic heart disease. Objectives Our study is a prospective cross-sectional controlled study that aims to study the effect of cardiac rhythm on serum levels of the inflammatory mediators; C-Reactive Protein and Interleukin-6 in patients with chronic rheumatic heart disease. Methods The study included 70 rheumatic heart disease patients on regular long acting penicillin. Patients were divided into to 2 groups: Group A; 56 patients with rheumatic heart disease who have sinus rhythm, and Group B; 14 patients with rheumatic heart disease who have atrial fibrillation (AF) and Group C; control group of 10 healthy individuals. Results There was no significant difference between sinus patients and AF patients in CRP and IL-6 levels (p = 0.3050 and 0.6758, respectively). Also, there was no significant difference between 15, 21 and 30 days regimens of penicillin in CRP and IL-6 levels (p = 0.9467and 0.0795, respectively). IL6 values were significantly correlated with CRP values (r = 0.5435, p &lt; 0.0001). There was a significant difference in CRP and IL-6 levels between compliant and non-compliant patients (p = 0.0053 and 0.0308). Conclusion Our study results disprove that cardiac rhythm has an effect on the serum levels of the inflammatory mediators C-Reactive Protein and Interleukin-6 in chronic rheumatic heart disease. Our study also disproves the preference of any regimen of long acting penicillin (15 days, 21 days and 30 days) over each other for secondary prevention of chronic rheumatic heart disease. Our study results emphasized that chronic rheumatic heart disease is an inflammatory process mediated with some mediators as CRP and IL-6 that are strongly correlated with each other.

Association of IL-4 (intron 3) and IL-10 (-1082) gene polymorphisms with risk of mitral valve disease in children with rheumatic heart disease

2015 ◽  
Vol 26 (7) ◽  
pp. 1290-1296 ◽  
Author(s):  
Sherif M. Yousry ◽  
Yasser Sedky ◽  
Alaa Sobieh
Keyword(s):  
Heart Disease ◽  
Mitral Valve ◽  
Rheumatic Heart Disease ◽  
Mitral Valve Disease ◽  
Gene Polymorphisms ◽  
Cardiac Tissue ◽  
Valve Disease ◽  
Egyptian Children ◽  
Significant Difference ◽  
Rheumatic Heart

AbstractAimRheumatic heart disease is an inflammatory disease of cardiac tissue. The underlying pathogenic mechanisms highlight a complex interplay of immunological, genetic, and environmental factors. The aim of the present study was to investigate whether IL-4 (intron 3) and IL-10 (-1082) gene polymorphisms could be associated with susceptibility and/or severity of rheumatic heart disease among patients from the Egyptian population.Materials and methodsA cohort of 140 Egyptian children with rheumatic heart disease and 100 healthy controls were enrolled in this case–control study. Genotyping for IL-4 (intron 3) and IL-10 (-1082) gene polymorphisms was carried out for all patients using a polymerase chain reaction-based analysis.ResultsNo significant difference in the distribution of genotypes and allelic frequencies between rheumatic heart disease cases and controls for IL-4 (intron 3) (p=0.17; OR 1.07, 95% CI 0.82–3.74) and IL-10 (-1082) (p=0.49; OR 1.03, 95% CI 0.65–2.71) gene polymorphisms was observed. Further categorisation of patients into mitral valve disease and combined valve disease subgroups showed that cases with mitral valve disease have significantly higher frequency of the RP2 allele of IL-4 (intron 3) (p=0.03; OR 2.98, 95% CI 1.93–6.15) and the G allele of IL-10 (-1082) (p=0.04; OR 2.14, 95% CI 1.62–4.95) when compared with controls.DiscussionOur study shows that IL-4 (intron 3) and IL-10 (-1082) gene polymorphisms are not significantly associated with susceptibility to rheumatic heart disease, but they might play a role in the pathogenesis of patients with mitral valve disease.

scholarly journals The effect of gene polymorphism of certain cytokines on echocardiographic parameters in patients with chronic rheumatic heart disease

2019 ◽  
pp. 42-47
Author(s):  
V. S. Petrov
Keyword(s):  
Heart Disease ◽  
Left Ventricle ◽  
Rheumatic Heart Disease ◽  
Left Ventricular ◽  
Right Heart ◽  
Linear Dimensions ◽  
Tnf Α ◽  
Significant Difference ◽  
Echocardiographic Parameters ◽  
Rheumatic Heart

Aim.To assess the effect of polymorphism of tumor necrosis factor-а (TNF-α) cytokines and interleukin (IL-17A, IL-17F, IL-10) on echocardiographic parameters in patients with chronic rheumatic heart disease (RHD).Material and methods. A total of 128 patients with RHD were examined, average age was 58,96±0,34 years. Echocardiography was performed on a Philips Affinity 50 machine. Genotyping was carried out using polymorphic TNF-α markers (G308A, IL-10 G1082A, IL-17A G197A, IL-17F А161Н0 by polymerase chain reaction with an electrophoretic scheme for detecting the result of “SNP-EXPRESS”.Results. RHD homozygotes for TNF-а A308A had the largest linear dimensions of the left ventricle (left ventricle end-diastolic dimension (LVED) — 5,80±0,22 cm, left ventricle end-systolic dimension (LVES) — 3,93±0,27 cm), as well as the studied homozygous for IL-17A A197A (LVED — 5,81±0,13 cm, LVES — 3,78±0,11 cm). In group of TNF-α G308G homozygotes, values of right heart (right ventricle — 2,75±0,05 cm, right atrium — 4,80±0,11 cm) were the largest and mitral valve orifice area (MVOA) was smallest — 1,52±0,04 cm2. Heterozygous patients with IL-17F Д161Н also had a greater dilatation of the ventricles compared with homozygotes of IL-17F Н161Н, in which parameters were close to normal (LVED 5,58±0,05 cm, LVES 3,68±0,04 cm). There was no statistically significant difference in linear sizes of the left and right heart in patients with IL-10 polymorphism. IL-10 polymorphism patients had statistically significant MVOA differences: minimum MVOA in G1082A heterozygotes — 1,40±0,06 cm2and maximum — 1,64±0,04 cm2in G1082G homozygotes. IL-10 G1082G homozygotes was characterized by maximum values of interventricular septum — 1,13±0,04 cm, left ventricular posterior wall — 1,10±0,03 cm.Conclusion. Homozygosity of TNF-α A308A and IL-17A A197A in RHD patients leads to the largest linear sizes of the left ventricle, and homozygosity for TNF-а G308G — to the maximum sizes of the right heart and left atrium against the background of the minimum sizes of MVOA. IL-10 polymorphism has not effect on heart linear dimensions, but IL-10 G1082G leads to maximum MVOA size.

scholarly journals Brain natriuretic peptide gene polymorphism in patients with congestive heart failure

2013 ◽  
Vol 94 (4) ◽  
pp. 433-438
Author(s):  
E N Berezikova ◽  
S D Mayanskaya ◽  
L A Garaeva ◽  
S N Shilov ◽  
A V Efremov ◽  
...  
Keyword(s):  
Heart Failure ◽  
Coronary Heart Disease ◽  
Congestive Heart Failure ◽  
Heart Disease ◽  
High Risk ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Clinical Course ◽  
Polymorphic Locus ◽  
Peptide Gene

Aim. To study the influence of brain natriuretic peptide gene polymorphism (polymorphic locus Т-381С) on brain natriuretic peptide serum level and congestive heart failure onset risk and clinical features in patients with coronary heart disease. Methods. 412 patients with congestive heart failure were examined. Genotyping was performed by polymerase chain reaction. Brain natriuretic peptide N-terminal fragment level was assessed by ELISA. The control group included 211 healthy controls with no signs of cardiovascular pathology on examination. Results. In healthy people with C/C genotype the level of brain natriuretic peptide N-terminal fragment was significantly higher in comparison with people carrying T/T genotype. It was found that the T allele and T/T genotype of the T-381C natriuretic peptide gene polymorphic locus was associated with high risk, severity and unfavorable clinical course of congestive heart failure in patients with coronary heart disease. At the same time, the C allele and C/C genotype emerged as a protective factor regarding the risk, severity and clinical course of the disease. Conclusion. T/T genotype carriers of the of the T-381C natriuretic peptide gene polymorphic locus are a special subgroup associated with high risk of congestive heart failure onset and unfavorable clinical course. Therefore these patients with coronary heart disease should be considered as a group requiring an out-patient control and preventive measures targeted on congestive heart failure and premature mortality prevention.

Sign in / Sign up

Export Citation Format

Share Document